

Daily evidence digest

1 April 2022

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Early ivermectin treatment, ruxolitinib, SARS-CoV-2 pathogenesis, Pfizer vaccine protection against Omicron in children and adolescents

Peer reviewed journals featured:

- Randomised controlled trials of:
 - Early treatment with ivermectin among COVID-19 patients [here](#)
 - Early outpatient treatment for COVID-19 with convalescent plasma [here](#)
 - Ruxolitinib plus standard of care for treating COVID-19 hospital patients [here](#) and associated commentary [here](#)
- A narrative review on SARS-CoV-2 pathogenesis [here](#)
- Observational studies on:
 - Comirnaty (Pfizer) protection against Omicron in children and adolescents [here](#)
 - The relationship between asthma and severe COVID-19 [here](#)
 - Telephone triage and predicting adverse outcomes in suspected COVID-19 [here](#)
 - Identifying 10 key research questions about the long-term sequelae of COVID-19 [here](#)
 - COVID-19 infection among incarcerated persons and prison staff in Lombardy, Italy [here](#)
 - COVID-19 booster vaccination among individuals with schizophrenia in Israel [here](#)
- Commentary on:
 - How data from the UK has guided COVID-19 vaccine policies [here](#)
 - Smart toilets for monitoring COVID-19 surges (COV-ID) [here](#)

Letters and correspondence discussed:

- Assessment of Mu variant emergence and spread in Colombia [here](#)
- Risk of hospitalisation and death in children with Delta infection [here](#)

News and blogs

- NHS staff will still have access to free tests [here](#)
- Americans who are over 50 or immunocompromised are advised to have second booster [here](#)
- COVID-19 antibody drugs work best when given as early as possible [here](#)

[Click here](#) to subscribe to the daily evidence digest